A new study found that almost all plans in 40 states and Washington, DC covered at least one form of the opioid overdose reversal drug naloxone, although certain restrictions and quantity limits may ...
Figure illustrates the proportion of Medicaid managed care plans (MCP) in state covering at least one generic injectable or generic or brand intranasal naloxone formulation without any restrictions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results